In this video, Dr. Bosl argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.
George J. Bosl, MD
In this paper, we review the use of serum tumor markers in risk assignment and response evaluation; the treatment of previously untreated and relapsing patients; the role of surgical resection of residual disease, including retroperitoneal node dissection; and the importance of clinical trials for addressing unanswered questions and testing new therapies.
Granulosa cell tumors of the testis are very rare neoplasms. While most appear to have a benign course, they occasionally metastasize.